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Introduction:   
Polycystic ovary syndrome (PCOS) is a complex endocrinopathy affecting 4-21% of women 
worldwide.  PCOS patients may present with gastrointestinal (GI) disturbances more often than 
healthy women. Irritable  Bowel Syndrome (IBS) is a functional GI system disorder affecting 10-20% of 
the general population.  Research shows that young females are most severely affected by IBS. Links 
between these conditions have  received limited attention in research thus far.   
Aim:   
To assess IBS prevalence based on the Rome IV diagnostic criteria in PCOS patient population and 
compare  findings with anthropometric, biochemical, hormonal, and QoL data.   
Materials and Methods:   
Participants included 133 PCOS patients and 72 age- and BMI-matched healthy women. PCOS 
diagnosis  was based on the Rotterdam criteria. The 2016 Rome IV IBS criteria were used. Metabolic 
syndrome (MS)  presence was evaluated with the current International Diabetes Federation criteria. 
Depressive symptoms  were assessed using the Center for Epidemiologic Studies Depression Scale - 
Revised (CESD-R) and  participants’ health-related QoL with the 15D instrument.   
Results:   
IBS prevalence was 24% in PCOS vs. 21% in controls (p=0.60). Among PCOS patients, 6.02% had  
previously diagnosed IBS compared to 8.06% of controls (p=0.60). There was no significant difference  
between depressive symptoms occurrence in PCOS+IBS (4.17%) vs. PCOS-only (4%). QoL appeared 
to be  significantly lower in PCOS+IBS patients vs. PCOS-only. Simple obesity, visceral obesity, and  
hyperandrogenism did not influence IBS prevalence in PCOS patients. Alarm symptoms were more 
common  in the PCOS group vs. controls. MS was more prevalent in IBS+PCOS vs. PCOS-only 
subjects.   
Conclusion:   
There seem to be no significant differences between IBS occurrence in PCOS vs. healthy women. 
Obesity,  hyperandrogenism, biochemical-hormonal disturbances seem not to affect IBS prevalence in 
PCOS. IBS  screening is advised in PCOS patients due to its potential negative impact on QoL.   
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